Fresenius SE & Co KGaA (FRA:FRE) PT Set at €50.00 by Credit Suisse Group

Fresenius SE & Co KGaA (FRA:FRE) received a €50.00 ($58.14) price target from Credit Suisse Group in a research note issued on Friday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. Credit Suisse Group’s price target would indicate a potential upside of 15.30% from the stock’s previous close.

FRE has been the subject of a number of other reports. Nord/LB set a €58.00 ($67.44) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Morgan Stanley set a €50.00 ($58.14) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Monday, September 30th. HSBC set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Thursday. JPMorgan Chase & Co. set a €58.40 ($67.91) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Thursday. Finally, Independent Research set a €51.00 ($59.30) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Friday, August 2nd. Nine analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Fresenius SE & Co KGaA currently has an average rating of “Buy” and an average target price of €57.93 ($67.36).

Shares of FRE stock opened at €43.37 ($50.42) on Friday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02). The stock has a 50 day moving average price of €43.63 and a 200 day moving average price of €46.49.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: How Do I Invest in Dividend Stocks

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.